Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2001 Nov;85(5):391–397. doi: 10.1136/adc.85.5.391

Safety of a new conjugate meningococcal C vaccine in infants

R Lakshman 1, I Jones 1, D Walker 1, K McMurtrie 1, L Shaw 1, G Race 1, S Choo 1, L Danzig 1, P Oster 1, A Finn 1
PMCID: PMC1718967  PMID: 11668101

Abstract

BACKGROUND—Group C conjugate meningococcal vaccines (Men C) were introduced into the UK primary immunisation schedule in November 1999.There has been extensive professional and public interest in their efficacy and safety.
AIM—To determine the occurrence of at least one uncommon adverse event in infants related to the administration of the Chiron Men C vaccine.
METHODS—A total of 2796 infants aged approximately 2 months were recruited into the study from areas in and around Sheffield and from Scotland. They were vaccinated with the Chiron Men C vaccine at 2, 3, and 4 months along with routine immunisations. Data on adverse events occurring one month after each dose were collected actively and prospectively and reviewed for possible relation to the vaccine.
RESULTS—There were no deaths. There were no serious adverse events considered definitely or probably caused by the vaccine. Four infants developed serious adverse events (hypotonia, screaming syndrome, maculopapular rash, and agitation, respectively) that were considered possibly related to the vaccine. All recovered completely. Adverse events were seen in 1804 children but were considered possibly related to the vaccine in only 49 (1.8%). On subsequent immunisation there were no recurrences of adverse events considered to be possibly related to the vaccine.



Full Text

The Full Text of this article is available as a PDF (160.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bramley J. C., Hall T., Finn A., Buttery R. B., Elliman D., Lockhart S., Borrow R., Jones I. G. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001 Apr 6;19(20-22):2924–2931. doi: 10.1016/s0264-410x(00)00528-4. [DOI] [PubMed] [Google Scholar]
  2. Choo S., Zuckerman J., Goilav C., Hatzmann E., Everard J., Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000 Jun 1;18(24):2686–2692. doi: 10.1016/s0264-410x(00)00050-5. [DOI] [PubMed] [Google Scholar]
  3. Decker M. D., Edwards K. M., Steinhoff M. C., Rennels M. B., Pichichero M. E., Englund J. A., Anderson E. L., Deloria M. A., Reed G. F. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995 Sep;96(3 Pt 2):557–566. [PubMed] [Google Scholar]
  4. English M., MacLennan J. M., Bowen-Morris J. M., Deeks J., Boardman M., Brown K., Smith S., Buttery J., Clarke J., Quataert S. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine. 2000 Dec 8;19(9-10):1232–1238. doi: 10.1016/s0264-410x(00)00241-3. [DOI] [PubMed] [Google Scholar]
  5. MacDonald N. E., Halperin S. A., Law B. J., Forrest B., Danzig L. E., Granoff D. M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998 Nov 18;280(19):1685–1689. doi: 10.1001/jama.280.19.1685. [DOI] [PubMed] [Google Scholar]
  6. MacLennan J. M., Shackley F., Heath P. T., Deeks J. J., Flamank C., Herbert M., Griffiths H., Hatzmann E., Goilav C., Moxon E. R. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA. 2000 Jun 7;283(21):2795–2801. doi: 10.1001/jama.283.21.2795. [DOI] [PubMed] [Google Scholar]
  7. Ramsay M. E., Andrews N., Kaczmarski E. B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001 Jan 20;357(9251):195–196. doi: 10.1016/S0140-6736(00)03594-7. [DOI] [PubMed] [Google Scholar]
  8. Rennels M. B., Edwards K. M., Keyserling H. L., Reisinger K., Blatter M. M., Quataert S. A., Madore D. V., Chang I., Malinoski F. J., Hackell J. G. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J. 2001 Feb;20(2):153–159. doi: 10.1097/00006454-200102000-00007. [DOI] [PubMed] [Google Scholar]
  9. Rennels M. B. The rotavirus vaccine story: a clinical investigator's view. Pediatrics. 2000 Jul;106(1 Pt 1):123–125. doi: 10.1542/peds.106.1.123. [DOI] [PubMed] [Google Scholar]
  10. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., Miller E. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun. 2001 Apr;69(4):2378–2382. doi: 10.1128/IAI.69.4.2378-2382.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., Begg N., Morris R., Cartwright K. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999 Jun;179(6):1569–1572. doi: 10.1086/314753. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES